Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept in De Novo Liver Transplant
NCT00555321Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2008
- Primary completion
- Mar 2010
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of belatacept in Liver transplant rejection (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Percentage of Participants Who Experienced at Least One Episode of Acute Rejection (AR), Graft Loss, or Death at 6 months and Number of Participants Who Had Adverse Events (AEs), Death, Serious AEs (SAEs) or Were Discontinued Due to AEs. Started Jan 2008; status: terminated.
02
Drugs
belatacept
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT00555321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00555321.